Nageswara Rao Alla
The search for a HIV vaccine that can elicit potent, long lasting and broad immune responses to both prevent acquisition of infection and control viral replication has been going on for over two decades. The modest success of the RV144 vaccine efficacy trial and isolation of broadly neutralizing antibodies capable of neutralizing different HIV strains has reinvigorated research in antibody based vaccine design and development strategies. This review will discuss the efficacy trials conducted to date, lessons learned from the trials, challenges and current strategies being pursued in the HIV vaccine field.
Comparte este artículo